OBJECTIVE: The inflammatory biomarker YKL-40 is elevated and associated with mortality in patients with stable coronary artery disease (CAD). The aim was to investigate the influence of statin treatment and lipid status on serum YKL-40 and Hs-CRP in patients with stable CAD. DESIGN: Serum YKL-40, HsCRP, total cholesterol, HDL-c, LDL-c and triglycerides levels were measured in 404 statin treated and in 404 matched non-statin treated patients with stable CAD. RESULTS: YKL-40 was significantly higher in non-statin treated 110 µg/l (median) compared with 65 µg/l in statin treated (p < 0.001). HsCRP was 3.3 mg/l in non-statin treated compared with 2.1 mg/l in statin treated (p < 0.001). YKL-40 was not related to cholesterol levels for either statin or non-statin treated patients in the univariate analysis. In statin treated patients, HsCRP was related to a high level of total-cholesterol (p = 0.01) and a low level of HDL-c (p < 0.001). CONCLUSIONS: HsCRP, but not YKL-40, is associated with the cholesterol levels in statin treated patients. This indicates that YKL-40 could be a superior prognostic biomarker in patients with stable CAD, since it is independent of changes in cholesterol levels in both statin and non-statin treated patients.
OBJECTIVE: The inflammatory biomarker YKL-40 is elevated and associated with mortality in patients with stable coronary artery disease (CAD). The aim was to investigate the influence of statin treatment and lipid status on serum YKL-40 and Hs-CRP in patients with stable CAD. DESIGN: Serum YKL-40, HsCRP, total cholesterol, HDL-c, LDL-c and triglycerides levels were measured in 404 statin treated and in 404 matched non-statin treated patients with stable CAD. RESULTS:YKL-40 was significantly higher in non-statin treated 110 µg/l (median) compared with 65 µg/l in statin treated (p < 0.001). HsCRP was 3.3 mg/l in non-statin treated compared with 2.1 mg/l in statin treated (p < 0.001). YKL-40 was not related to cholesterol levels for either statin or non-statin treated patients in the univariate analysis. In statin treated patients, HsCRP was related to a high level of total-cholesterol (p = 0.01) and a low level of HDL-c (p < 0.001). CONCLUSIONS: HsCRP, but not YKL-40, is associated with the cholesterol levels in statin treated patients. This indicates that YKL-40 could be a superior prognostic biomarker in patients with stable CAD, since it is independent of changes in cholesterol levels in both statin and non-statin treated patients.
Authors: R G Boot; T A van Achterberg; B E van Aken; G H Renkema; M J Jacobs; J M Aerts; C J de Vries Journal: Arterioscler Thromb Vasc Biol Date: 1999-03 Impact factor: 8.311
Authors: B Volck; P A Price; J S Johansen; O Sørensen; T L Benfield; H J Nielsen; J Calafat; N Borregaard Journal: Proc Assoc Am Physicians Date: 1998 Jul-Aug
Authors: Paul M Ridker; Eleanor Danielson; Francisco Ah Fonseca; Jacques Genest; Antonio M Gotto; John Jp Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G Macfadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn Journal: Lancet Date: 2009-03-28 Impact factor: 79.321
Authors: Camilla Noelle Rathcke; Frederik Persson; Lise Tarnow; Peter Rossing; Henrik Vestergaard Journal: Diabetes Care Date: 2008-10-28 Impact factor: 19.112
Authors: Anders R Nielsen; Christian Erikstrup; Julia S Johansen; Christian P Fischer; Peter Plomgaard; Rikke Krogh-Madsen; Sarah Taudorf; Birgitte Lindegaard; Bente K Pedersen Journal: Diabetes Date: 2008-07-23 Impact factor: 9.461
Authors: Stine B Thomsen; Anette P Gjesing; Camilla N Rathcke; Claus T Ekstrøm; Hans Eiberg; Torben Hansen; Oluf Pedersen; Henrik Vestergaard Journal: PLoS One Date: 2015-07-21 Impact factor: 3.240